Tumor-reactive T cells represent a small subset within the often densely infiltrated tumor microenvironment. These cells can specifically detect cancer-specific antigens—unique proteins expressed on tumor cells—and execute immune responses to eradicate malignancies. However, given the heterogeneity and mutability of tumors, antigens vary widely even within a single tumor, complicating the selection of appropriate T cells for therapeutic use. Conventional approaches depend on knowing specific antigens in advance, limiting their utility and efficiency.

The ATTACH platform circumvents this limitation by exploiting the tumor itself as a presentation source for natural, native cancer antigens. By co-incubating T cells derived from tumors with live cancer cells under controlled microfluidic conditions, the platform measures the avidity—or binding strength—between them. Gentle fluid flows then wash away T cells with weaker or non-specific interactions, enriching for the most avid and thus potentially most tumor-reactive T cells. This selective process significantly boosts the yield of cancer-specific T cells, reportedly increasing their relative proportion up to tenfold even when starting with extremely rare populations.

Importantly, ATTACH maintains the functional integrity of isolated T cells, preserving their tumor-killing capabilities without requiring specialized instrumentation commonly associated with such isolations. This user-friendly, scalable technology offers a robust tool for both basic research and clinical applications, potentially accelerating the creation of personalized immunotherapies tailored to an individual’s unique tumor profile.

The research, led by Dr. Alexandre Reuben and collaborators at MD Anderson, was published in the Journal for ImmunoTherapy of Cancer. It highlights how harnessing intrinsic cell-to-cell interactions can unlock new avenues for immune precision medicine. By allowing direct identification of effective T cells without the constraints of predefined antigen knowledge, ATTACH paves the way for next-generation immunotherapies with improved specificity and efficacy.

This advancement comes at a critical time when cancer immunotherapy continues to revolutionize treatment paradigms, yet faces challenges in isolating potent tumor-reactive lymphocytes. ATTACH offers a promising strategy to overcome these bottlenecks, potentially translating into faster development timelines and better patient outcomes. The platform’s reliance on biophysical properties of immune-cancer cell binding rather than genetic or molecular markers marks a novel direction in cancer immunology technology.

By providing an adaptable framework to enrich rare, therapeutically valuable immune cells directly from tumors, ATTACH could significantly impact both research and clinical workflows. The ability to readily capture the “best-fit” T cells might enhance the effectiveness of adoptive cell therapies and inform the design of vaccines and combination treatments, reinforcing the arsenal against cancer.

Subject of Research: Tumor-reactive T cell isolation and cancer immunotherapy development
Article Title: Information not provided
News Publication Date: July 8, 2026
Web References: https://jitc.bmj.com/content/14/7/e014960
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: Cancer immunology, Tumor-reactive T cells, Immunotherapy, Microfluidics, Immune response, Antigens

Historically, breast cancer risk evaluations have been predominantly predicated on hereditary factors, including well-characterized genetic mutations, yet these only elucidate a fraction—approximately 6%—of cases. For women without known genetic predisposition or family history, risk stratification has remained imprecise and often reliant on indirect methodologies such as mammographic breast density. These traditional approaches risk misclassification, leading to both over-diagnosis and missed early warning signs. The newly devised platform catalyzes a paradigm shift by delivering a direct, biophysical measure embedded within the cells themselves.

At the heart of this innovation lies a microfluidic device designed to “squeeze” individual epithelial cells through narrow channels, functionally mimicking biomechanical stressors. The platform captures how rapidly and effectively these cells deform and subsequently recover their shape, markers indicative of their mechanical properties—parameters termed as “mechanical age.” This concept, borrowed from material engineering disciplines that study wear and fatigue in metals and polymers, is applied here for the first time to living cells, bridging engineering principles with cellular biology in a novel fusion.

The team’s approach heavily leverages computational advancements through the integration of machine learning algorithms. By training with extensive datasets derived from cells of varying ages and genetic risk profiles, the algorithm quantitatively discerns cells exhibiting premature mechanical aging signatures — cells that, while from younger individuals, present deformation behaviors reminiscent of aged cells. These findings not only validate the mechanical age hypothesis but also correlate directly with heightened breast cancer risk, including in individuals harboring high-risk genetic mutations.

Unlike other cell mechanics measurement techniques, such as atomic force microscopy or advanced optical imaging, the MechanoAge platform circumvents the need for prohibitively expensive and complex instrumentation. Instead, it utilizes widely accessible electronic components akin to those found in common devices, ensuring affordability and scalability. This factor alone holds transformative potential for widespread clinical implementation, democratizing access to early and precise breast cancer risk detection.

The microfluidic device operates on the principle of mechano-node-pore sensing, wherein the translocation of cells through liquid-filled, electronically monitored channels disrupts an electrical current. These disruptions translate into real-time metrics on cellular size, shape, and deformability. Narrow constrictions strategically incorporated in the channels induce mechanical challenge, while the system records recovery dynamics with high temporal resolution. The quantifiable parameters extracted provide an integrative index reflective of cellular health and mechanical resilience.

A particularly revealing outcome of this investigation is the disconnect observed between chronological age and mechanical cellular age. Some younger women’s cells displayed stiffness and prolonged recovery indicative of advanced mechanical aging. This discrepancy uncovers a layer of biological complexity that conventional risk assessment tools overlook, emphasizing the capacity of MechanoAge to identify subtle phenotypic variations that predicate cancer development.

Validation studies using samples from a diverse cohort — comprising healthy individuals, those with familial breast cancer history, and patients with unilateral breast cancer — demonstrated the platform’s accuracy in differentiating high-risk profiles. The derived risk scores closely aligned with known genetic susceptibilities and clinical diagnoses, underscoring the platform’s potential as a precision medicine tool that guides tailored screening regimens.

The collaborative nature of this research, spanning over a decade, merges deep expertise from cancer biology and mechanical engineering. The continuous exchange of insights between these disciplines fostered a holistic understanding vital to advancing from conceptualization to application. Researchers emphasize that this longitudinal partnership was instrumental in achieving these unanticipated yet impactful discoveries.

Looking forward, the MechanoAge platform might reshape breast cancer screening paradigms, enabling earlier, more accurate detection of risk at an individual cell level well before tumors manifest clinically. Such a shift promises to reduce unnecessary interventions while enhancing vigilance for those at genuine heightened risk. Furthermore, with the device’s affordability and portability, it could see deployment beyond specialized centers, reaching underserved populations globally.

This novel assessment method also holds promise beyond cancer, potentially applicable to other age-related diseases where cellular mechanical properties influence pathology. The framework combining microfluidics and artificial intelligence illustrates a broader trend towards integrating engineering innovation with biomedical discovery, heralding a new epoch of personalized medicine driven by cellular phenotyping.

The research was generously supported by multiple grants from the National Institutes of Health and the American Cancer Society, reflecting a critical investment in transformative translational science. The authors disclosed no competing interests, though relevant patent applications underscore the groundbreaking nature of this technology, laying groundwork for future commercialization efforts.

In summation, the MechanoAge platform represents a paradigm shift, advancing breast cancer risk assessment by quantifying the mechanical behavior of single cells. By applying engineering principles to biology, it illuminates hidden dimensions of cellular aging and risk—ushering in an era of individualized, mechanobiologically informed cancer prevention and early detection.

Subject of Research: Cells

Article Title: MechanoAge, a machine learning platform to identify individuals susceptible to breast cancer based on mechanical properties of single cells

News Publication Date: 23-Apr-2026

Image Credits: City of Hope and UC Berkeley

Keywords

Breast cancer, Microfluidics, Engineering, Epidemiology, Personalized medicine, Machine learning, Artificial intelligence